Loading news...
West Pharmaceutical Services (NYSE: WST - Get Free Report) and Henry Schein (NASDAQ: HSIC - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Valuation and Earnings This table compares West
EXTON, Pa., Feb. 27, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Barclays Global Healthcare Conference: Fireside chat at 9:00 AM EDT on Tuesday, March 10, 2026 KBCM Healthcare Forum: Fireside chat at 1:30 PM EDT on Wednesday, March 18, 2026 The live webcasts for these events can be accessed in the Investors section of the Company's website. A replay of each webcast will also be available on the Company's website for approximately 90 days after each respective event.
Artisan Partners Limited Partnership grew its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 22.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,770,920 shares of the medical instruments supplier's stock after purchasing an additional 503,601 shares
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The mean of analysts' price targets for West Pharmaceutical (WST) points to a 32.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EXTON, Pa., Feb. 17, 2026 /PRNewswire/ -- On February 16, 2026, the Board of Directors of West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, declared its regular quarterly dividend of $0.22 per share on the Company's common stock. The dividend is payable on May 6, 2026 to shareholders of record on April 29, 2026.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
West Pharmaceutical Services just sent investors $0.22 per share on February 4, 2026, marking the company's latest quarterly dividend payment.
Cibc World Market Inc. grew its position in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 300.0% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,586 shares of the medical instruments supplier's stock after buying an additional 13,940 shares
Caprock Group LLC purchased a new position in shares of West Pharmaceutical Services, Inc. (NYSE: WST) during the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,965 shares of the medical instruments supplier's stock, valued at approximately $1,473,000. Several other hedge funds and
Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either The Cooper Companies (COO) or West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
West Pharmaceutical Services, Inc. (WST) Q4 2025 Earnings Call Transcript
West Pharmaceutical beats Q4 EPS and revenue estimates as proprietary products drive growth, while shares jump nearly 3.6% premarket on upbeat 2026 outlook.
Although the revenue and EPS for West Pharmaceutical (WST) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.83 per share. This compares to earnings of $1.82 per share a year ago.
West Pharmaceutical forecast annual profit above Wall Street estimates on Thursday, after beating fourth-quarter expectations on strong demand for its proprietary products, which include syringes and cartridges for injectable drugs.
– Strong 4Q results, driven by double-digit organic revenue growth in HVP Components – – Introduces Fiscal 2026 Financial Guidance – EXTON, Pa., Feb. 12, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today reported its financial results for the fourth quarter and full year 2025.
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for West Pharmaceutical (WST), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.
Rockland Trust Co. boosted its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 6.5% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 83,066 shares of the medical instruments supplier's stock after purchasing an additional 5,087 shares during the period.
West Pharmaceutical heads into Q4 with HVP demand likely lifting margins, but tariff risk looms as revenue and EPS targets come into focus.